Jackie D.
Kendall
*ab,
Andrew J.
Marshall
a,
Anna C.
Giddens
a,
Kit Yee
Tsang‡
a,
Maruta
Boyd
a,
Raphaël
Frédérick§
a,
Claire L.
Lill
c,
Woo-Jeong
Lee
c,
Sharada
Kolekar
c,
Mindy
Chao
c,
Alisha
Malik
c,
Shuqiao
Yu
c,
Claire
Chaussade¶
bc,
Christina M.
Buchanan
bc,
Gordon W.
Rewcastle
ab,
Bruce C.
Baguley
ab,
Jack U.
Flanagan
ab,
William A.
Denny
ab and
Peter R.
Shepherd
bc
aAuckland Cancer Society Research Centre, School of Medical and Health Sciences, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand. E-mail: j.kendall@auckland.ac.nz
bMaurice Wilkins Centre for Molecular Biodiscovery, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
cDepartment of Molecular Medicine and Pathology, School of Medical and Health Sciences, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand
First published on 30th October 2013
As part of our investigation into the pyrazolo[1,5-a]pyridines as novel PI3K inhibitors, we report a range of analogues where the central linker portion of the molecule was varied while retaining the pyrazolo[1,5-a]pyridine and arylsulfonyl or arylcarbonyl groups. Isostere generating software BROOD was used to assist with producing ideas. The isoform selectivity of the compounds varied from pan-PI3K for compound 41 to p110α-selective for compound 58 or p110δ-selective for compound 57. The latter two compounds varied only in their sulphur oxidation state.
The PI3Ks are split into three sub-families (class I, II and III), and class I is further split into class Ia and Ib based upon their mechanism of activation. The class Ia PI3Ks are heterodimeric, consisting of a catalytic subunit (p110α, p110β or p110δ) in complex with a regulatory subunit.1 PIK3CA, the gene encoding for p110α, is often over-expressed and mutated in many cancer types. Two of the most common of these mutations (E545K and H1047R) have been confirmed as activating mutations and hence increase levels of PIP3.3 Mutations in p110β and p110δ have not been reported.4,5 Inhibitors of PI3K, and in particular, selective inhibitors of p110α could prove to be an important new strategy in cancer treatment.6 A number of inhibitors of PI3K are currently in clinical trials, although none have yet reached market.7,8
We have shown previously that pyrazolo[1,5-a]pyridines such as 1 (ref. 9) and 2 (ref. 10) (Fig. 1) are potent and selective inhibitors of the p110α isoform of PI3K. However, since the sulfonohydrazide central portion of the molecule is a known structural alert,11 we were interested in replacing this with an alternative linker group. This has been investigated to a limited extent by Hayakawa et al.12 with their related imidazo[1,2-a]pyridine series of compounds, however PI3K isoform selectivity data was not reported for all compounds.
Molecular modelling of the pyrazolo[1,5-a]pyridines showed that the pyrazolo nitrogen formed a key hydrogen bond with Val851 of p110α;9 a residue interaction characteristic of many other PI3K inhibitor complexes.13 Furthermore the sulfonyl group formed a hydrogen bond with the p110α specific residue Gln859,9 and the nitro group was also critical for good potency and selectivity.10 We postulated that linking the pyrazolo[1,5-a]pyridine and nitroaryl sulfonyl moieties in an appropriate way would generate a p110α selective PI3K inhibitor with lower toxicity.
We also chose some linker groups of our own devising: an allylic sulfone to mimic the shape of the sulfonohydrazide without containing the two nitrogens, a set of amine-containing linkers which could improve water solubility, and other heterocyclic linking groups.
Scheme 1 Reagents: (i) NIS, MeCN; (ii) acrolein, AcOH; (iii) iPrMgCl·LiCl, THF, −40 °C then 6; (iv) MsCl, DBU, MeCN. |
Cyclic amine derivatives 16–19 were made starting from amine 8 (ref. 9) (Scheme 2). Amine 8 was protected as either benzyl carbamate 9 or trifluoroacetamide 10, then iodinated at the 3-position to afford 11 and 12. Next, a palladium catalysed coupling with a cyclic vinyl boronate installed the amine ring. When 12 was used, the trifluoroacetamide protecting group was lost during this step. Hydrogenation over Pd/C then reduced the double bond from the amine ring and removed the benzyl carbamate to leave Boc protected compounds 13–15. Then diazotisation converted the free amine to a bromide and also removed the Boc group under the acidic conditions used, and finally sulfonylation or acylation afforded compounds 16–19.
Aminomethylene-linked compounds 23a–h and 24a–g which contain a basic amine to increase aqueous solubility were made by reductive amination of aldehyde 20 (ref. 9) to afford amines 21a–h (Scheme 3). Removal of the Boc group was then followed by sulfonylation to give sulfonamides 23a–h or acylation to give carboxamides 24a–g.
Thiazoles were made using a Hantzsch thiazole synthesis from an α-bromoketone and a thioamide. The syntheses of the required thioamides 29–34 are depicted in Scheme 4. Carboxylic acid 25 was converted to thioamide 29 by formation of the acid chloride followed by treatment with ammonia to give the primary amide, followed by thionation with Lawesson's reagent to give 29 in good yield. Benzylic chloride 26 was displaced with potassium cyanide to give the phenylacetonitrile intermediate, which was subsequently reacted with phosphorous pentasulfide in ethanol under mild conditions to give thioamide 30.15 Dithiocarbamate 31 was also prepared from 26 by firstly converting it to the more reactive bromide followed by displacement with a large excess of ammonium dithiocarbamate.16 Sulfonyl chloride 27 was reacted with cyanamide, followed by thiolysis using in situ generation of thiosulfuric acid to give thiourea 32. Thioamide 33 was accessed by displacement of bromoacetonitrile with the sulfinate salt of 27 to give the nitrile, which underwent thiolysis with hydrogen sulfide. Thiourea 34 was prepared from aniline 28 by reaction with benzoyl isothiocyanate followed by hydrolysis according to published routes.17,18
Methylketone 35 (ref. 9) was brominated under standard conditions to give versatile intermediate α-bromoketone 36, which underwent a modified Hantzsch reaction with thioamides 29–34 to give thiazoles 37–42 (Scheme 5). Thioether 39 was oxidized with MMPP (magnesium bis(monoperoxyphthalate)) to give sulfone 43. Sulfonamide 40 was methylated with methyl iodide under mild conditions to give two regioisomeric products 44 and 45. The sites of methylation were identified by NMR experiments. N-Methylsulfonamide 44 showed NOE interactions between the N-methyl protons (3.65 ppm) and those of the aryl methyl protons (2.67 ppm) and aryl C6–H (8.88 ppm), whereas N-methylthiazole 45 had NOE interactions between the N-methyl protons (3.46 ppm) and pyrazolo[1,5-a]pyridine C2–H (7.97 ppm) and C4–H (7.65 ppm).
Scheme 5 Reagents: (i) Br2, 33% HBr/AcOH, (ii) 29–34, EtOH; (iii) MMPP, CH2Cl2, EtOH, H2O, (iv) MeI, DMF. |
2-Thiothiazoles 47, 50, 52 and 55 were accessed via copper-mediated coupling19 of thione 46 with phenyl boronic acids to give moderate yields of the desired thioethers (Scheme 6). Thione 46 could be prepared in good yield by reaction of α-bromoketone 36 with fresh ammonium dithiocarbamate. Oxidation with either Oxone® or MMPP gave the sulfoxide and/or sulfone, depending on the substrate and choice of oxidant. Oxone® oxidation of 47 gave exclusively sulfoxide 48, and MMPP oxidation afforded sulfone 49. MMPP oxidation of the more sterically hindered 2-methylphenyl compound 50 gave only sulfoxide 51 under microwave heating, whereas 5-cyano-2-fluorophenyl compound 52 afforded a mixture of sulfoxide 53 and sulfone 54 after reaction with the same reagent at room temperature. In contrast, 55 which did not bear a 2-phenyl substituent gave exclusively sulfone 56, suggesting that the presence of an ortho-phenyl substituent had a detrimental effect on sulfur oxidation. Nucleophilic displacement of the activated 2- or 4-fluorobenzenes (53, 54 and 56) with alkyl amines at room temperature gave the corresponding amino derivatives 57–60.
Cmpd | IC50 (μM) | Cmpd | IC50 (μM) | ||||
---|---|---|---|---|---|---|---|
p110α | p110β | p110δ | p110α | p110β | p110δ | ||
a Data from ref. 9. | |||||||
1 | 0.0009 | 0.046 | 0.049 | 37 | >1 | >1 | >1 |
7 | 0.14 ± 0.05 | >1 | 3.35 ± 0.41 | 38 | >1 | >1 | >1 |
16 | 3.00 ± 0.80 | >1 | >1 | 39 | >1 | >1 | >1 |
17 | 0.59 ± 0.20 | >1 | >1 | 40 | 1.26 ± 0.41 | >1 | >1 |
18 | >1 | >1 | >1 | 41 | 0.24 ± 0.13 | 0.14 ± 0.01 | 0.09 ± 0.05 |
19 | >1 | >1 | >1 | 42 | >1 | >1 | >1 |
23a | >1 | >1 | >1 | 43 | >1 | >1 | >1 |
23b | >1 | >1 | >1 | 44 | >1 | >1 | 1.55 ± 0.27 |
23c | >1 | >1 | >1 | 45 | >1 | >1 | >1 |
23d | >1 | >1 | >1 | 47 | >1 | >1 | >1 |
23e | >1 | >1 | >1 | 48 | 0.74 ± 0.01 | 4.42 ± 1.83 | 0.32 ± 0.17 |
23f | >1 | >1 | >1 | 49 | 0.63 ± 0.18 | 5.45 ± 0.30 | 0.25 ± 0.05 |
23g | >1 | >1 | >1 | 51 | 1.28 ± 0.22 | >1 | >1 |
23h | >1 | >1 | >1 | 53 | 0.30 ± 0.01 | >1 | 0.20 ± 0.03 |
24a | >1 | >1 | >1 | 54 | 0.72 ± 0.02 | >1 | 0.44 ± 0.03 |
24b | >1 | >1 | >1 | 56 | 0.17 ± 0.02 | >1 | 0.15 ± 0.12 |
24c | >1 | >1 | >1 | 57 | 4.03 ± 1.65 | 4.34 ± 1.76 | 0.25 ± 0.03 |
24d | >1 | >1 | >1 | 58 | 0.37 ± 0.15 | 3.56 ± 0.08 | 2.00 ± 0.48 |
24e | >1 | >1 | >1 | 59 | 2.47 ± 0.69 | >1 | 0.64 ± 0.14 |
24f | >1 | >1 | >1 | 60 | 2.13 ± 0.29 | >1 | 0.24 ± 0.13 |
24g | >1 | >1 | >1 |
Replacement of the hydrazone with allylic sulfone 7, where the hydrazone nitrogens atoms were replaced by carbons, was 150-fold less active against p110α than 1, while retaining some selectivity over p110β and p110δ. None of the cyclic amine derivatives 16–19, 23a–h and 24a–g had IC50 less than 1 μM for any of the class Ia PI3K isoforms, with the sole exception of 3-substituted piperidine 17 with a modest p110α IC50 of 0.59 μM. These compounds were not investigated further, and we instead focussed our efforts on aromatic heterocyclic linker groups.
Of the 2-methyl-5-nitrophenyl compounds 37–45, only 41 had p110α IC50 less than 1 μM, however this compound lost all selectivity for p110α over the other class Ia PI3K isoforms (p110α/β/δ IC50 0.24/0.14/0.09 μM). By comparison of 3-nitrophenyl compounds 47, 48 and 49, the addition of at least one oxygen on sulfur was necessary for p110α IC50 less than 1 μM although there was little difference between sulfoxide 48 and sulfone 49 (p110α IC5048: 0.74 μM and 49: 0.63 μM). Both 48 and 49 were less than 10-fold selective over p110β but were slightly more potent against p110δ than p110α.
The removal of the nitro group (51) decreased p110α activity in comparison to 48 by 2-fold. Benzonitrile derivatives 53, 54 and 56–60 all demonstrated PI3K IC50 of less than 1 μM against at least one of the class Ia isoforms, however the selectivity varied with the nature of the other phenyl substituent and sulfur oxidation state. Fluorophenyl compounds 53, 54 and 56 all had p110α IC50 under 1 μM and were all similarly active against p110δ. In contrast, amine-containing compounds 57, 59 and 60 all demonstrated modest selectivity, albeit for p110δ over p110α (by 16-fold, 4-fold and 9-fold, respectively). In contrast 58, the sulfone analogue of sulfoxide 57, was 5-fold selective for p110α over p110δ.
Footnotes |
† Electronic supplementary information (ESI) available. See DOI: 10.1039/c3md00221g |
‡ Present address: Universal Display Corporation, Hong Kong. |
§ Present address: Université Catholique de Louvain (UCL), Louvain Drug Research Institute, Medicinal Chemistry Research Group, 73 Avenue E. Mounier, bte B1.73.10, B-1200 Brussels, Belgium. |
¶ Present address: Centre Hospitalier Universitaire de Nice, Nice, France. |
This journal is © The Royal Society of Chemistry 2014 |